1-2 of 2
Pierre Feugier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract S09-02: High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy

Sylvain Lamure, Remy Dulery, Marc Delord, Roberta Di Blasi, Adrien Chauchet, Thomas Hueso, Cédric Rossi, Bernard Drenou, Bénédicte Deau-Fischer, Carole Soussain, Pierre Feugier, Nicolas Noel, Sylvain Choquet, Serge Bologna, Bertrand Joly, Laure Philippe, Milena Kohn, Sandra Malak, Guillemette Fouquet, Etienne Daguindau, Sophie Bernard, Yassine Taoufik, Karine Lacombe, Guillaume Cartron, Catherine Thieblemont
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6_Supplement): S09-02.
https://doi.org/10.1158/1557-3265.COVID-19-21-S09-02
Published: 15 March 2021
View article titled, Abstract S09-02: High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy
Journal Articles

The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association

Robert Kridel, Luc Xerri, Bénédicte Gelas-Dore, King Tan, Pierre Feugier, Ayesha Vawda, Danielle Canioni, Pedro Farinha, Sami Boussetta, Alden A. Moccia, Pauline Brice, Elizabeth A. Chavez, Alastair H. Kyle, David W. Scott, Ashley D. Sanders, Bettina Fabiani, Graham W. Slack, Andrew I. Minchinton, Corinne Haioun, Joseph M. Connors, Laurie H. Sehn, Christian Steidl, Randy D. Gascoyne, Gilles Salles
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (15): 3428–3435.
https://doi.org/10.1158/1078-0432.CCR-14-3253
Published: 02 August 2015
View article titled, The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
Open the PDF for The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association in another window
Includes: Supplementary data